Top Page
Tonix Pharma
(NASDAQ:TNXP)
Tonix Pharma (TNXP) vs. SPDR S&P 500 ETF (SPY)
Tonix Pharma Business Overview & Revenue Model
Tonix Pharma Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.11M | 10.09M | 7.77M | 0.00 | 0.00 |
| Gross Profit | 6.47M | 2.33M | 3.03M | 0.00 | 0.00 |
| EBITDA | -123.78M | -74.32M | -114.09M | -110.84M | -92.26M |
| Net Income | -124.02M | -130.04M | -116.66M | -110.22M | -92.29M |
Balance Sheet | |||||
| Total Assets | 277.17M | 162.89M | 154.46M | 225.69M | 240.90M |
| Cash, Cash Equivalents and Short-Term Investments | 207.64M | 98.78M | 24.95M | 120.23M | 178.66M |
| Total Debt | 1.31M | 5.30M | 9.81M | 760.00K | 956.00K |
| Total Liabilities | 32.02M | 23.33M | 48.93M | 18.51M | 22.18M |
| Stockholders Equity | 245.15M | 139.56M | 105.53M | 207.18M | 218.72M |
Cash Flow | |||||
| Free Cash Flow | -103.21M | -61.05M | -109.90M | -146.20M | -110.86M |
| Operating Cash Flow | -99.84M | -60.92M | -102.00M | -98.05M | -75.56M |
| Investing Cash Flow | -4.53M | -120.00K | -29.07M | -48.15M | -35.31M |
| Financing Cash Flow | 214.53M | 134.87M | 36.52M | 87.84M | 212.49M |
Tonix Pharma Technical Analysis
Tonix Pharma Risk Analysis
Tonix Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $311.29M | -3.77 | -110.72% | ― | ― | 77.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $177.73M | -21.41 | 11.28% | ― | 35.42% | ― | |
50 Neutral | $123.24M | -0.86 | -55.02% | ― | -46.92% | 20.26% | |
49 Neutral | $126.93M | -1.54 | -271.32% | ― | -75.77% | -31.24% | |
47 Neutral | $190.22M | -1.07 | -60.15% | ― | -8.79% | 81.36% | |
47 Neutral | $271.77M | -1.45 | -88.43% | ― | -76.59% | 94.03% |
Tonix Pharma Corporate Events
On March 10, 2026, Tonix Pharmaceuticals reported new clinical data on TONMYA (cyclobenzaprine HCl sublingual tablets) from two oral presentations at the 8th International Congress on Controversies in Fibromyalgia. The first presentation detailed results from the 14-week Phase 3 RESILIENT trial in 457 adults, showing rapid and statistically significant reductions in fibromyalgia pain versus placebo starting by Day 2 and sustained through Week 14, with all key secondary endpoints favoring TONMYA.
The second presentation pooled data from the RELIEF and RESILIENT Phase 3 trials, covering 959 participants, to clarify TONMYA’s benefit-risk profile using number needed to treat and harm metrics. The analysis found an NNT of 7 for achieving at least a 30% pain reduction over placebo at Week 14 and an NNH of 26 for discontinuation due to adverse events, yielding a likelihood to be helped or harmed of 3.7, indicating a substantially greater chance of clinical benefit than treatment-limiting side effects for fibromyalgia patients.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On March 3, 2026, Tonix Pharmaceuticals announced that Nasdaq approved the transfer of its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher-tier market commencing the same day under the ticker TNXP. The move acknowledges Tonix’s compliance with stricter financial and corporate governance standards and is expected to enhance its visibility, reputation and liquidity, potentially attracting more institutional investors and improving access to capital for future growth.
Management described the uplisting as an important milestone that may broaden market recognition among customers, partners and investors, signaling financial and operational progress to stakeholders. By joining Nasdaq’s highest market tier, Tonix positions itself alongside more established peers, which could support its efforts to build long-term shareholder value and strengthen its competitive standing in the biotechnology sector.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Tonix Pharma disclosed that the information related to its financial results or operations referenced in a specific filing section is being incorporated by reference into the current disclosure, without providing additional operational, strategic, or performance details in this release.
The most recent analyst rating on (TNXP) stock is a Sell with a $16.50 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On December 29, 2025, Tonix Pharmaceuticals entered into a securities purchase agreement with a single institutional investor for a registered direct offering comprising 615,025 shares of common stock and pre-funded warrants to purchase an additional 615,025 shares, at per-share and per-warrant prices of $16.26 and $16.259, respectively. The transaction, expected to close on or about December 30, 2025, is anticipated to generate approximately $20 million in gross proceeds and includes standard terms such as ownership caps on warrant exercises, short-term restrictions on Tonix issuing additional equity or variable-rate securities, and 30-day lock-up agreements for directors and officers; TD Securities (USA) LLC is acting as placement agent and will receive a 6% cash fee on the gross proceeds, underscoring Tonix’s continued reliance on equity-linked financings to support its operations and balance sheet while signaling to stakeholders a willingness to accept issuance constraints in exchange for near-term capital.
The most recent analyst rating on (TNXP) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On December 29, 2025, Tonix Pharmaceuticals announced updated plans for its TNX-4800 Lyme disease prophylaxis program, including a scheduled 2026 meeting with the U.S. Food and Drug Administration to explore Phase 2/3 development options and the potential use of a controlled human infection model involving Borrelia-infected ticks to demonstrate efficacy. The company reported results from a randomized, double-blind, dose-escalation study in 44 healthy adults showing that single subcutaneous doses up to 10 mg/kg were generally safe and well tolerated, with mostly mild or moderate adverse events, rapid systemic absorption, long-lasting serum levels measurable for up to 12 months, low incidence of anti-drug antibodies, and drug exposure well below levels associated with toxicity in animal studies, underscoring TNX-4800’s potential as an annually administered alternative to traditional Lyme vaccines and signaling a strategic step toward later-stage clinical development.
The most recent analyst rating on (TNXP) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
On December 16, 2025, Tonix Pharmaceuticals announced it has secured exclusive worldwide rights to TNX-4900, a promising non-opioid treatment for chronic neuropathic pain, from Rutgers University. This licensing agreement highlights Tonix’s strategic move to enhance its portfolio with a highly selective Sigma-1 receptor antagonist, which has shown significant efficacy and safety in preclinical models, potentially positioning the company as a leader in non-opioid pain management solutions.
The most recent analyst rating on (TNXP) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.